Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by Qh1234on Mar 31, 2017 8:14am
211 Views
Post# 26056678

Annual and qtr revenues are in line with Scotia's prediction

Annual and qtr revenues are in line with Scotia's predictionI noticed that PLI's annual and qtr revenues were in line with Scotia's expectation for year 2016.  The below is Scotia's revenue prediction.

Qtly Revenues (M)
 (Next Release: 30-Mar-17)
             Mar   Jun  Sep  Dec    Year
2014A   $6A  $4A  $2A  $11A  $23A
2015A   $2A  $3A  $6A  $14A  $25A
2016E   $5A  $3A  $4A  $3       $16
2017E                                       $62

GLTA
Bullboard Posts